A Double Blind Randomized Vehicle Controlled Crossover Study to Evaluate the Safety and Efficacy of Topical Naloxone Hydrochloride Lotion 0.5% for the Relief of Pruritus in Patients With the MF or SS Forms of Cutaneous T-Cell Lymphoma

Trial Profile

A Double Blind Randomized Vehicle Controlled Crossover Study to Evaluate the Safety and Efficacy of Topical Naloxone Hydrochloride Lotion 0.5% for the Relief of Pruritus in Patients With the MF or SS Forms of Cutaneous T-Cell Lymphoma

Recruiting
Phase of Trial: Phase III

Latest Information Update: 01 Nov 2017

At a glance

  • Drugs Naloxone (Primary)
  • Indications Cutaneous T cell lymphoma; Mycosis fungoides; Pruritus
  • Focus Registrational; Therapeutic Use
  • Sponsors Elorac
  • Most Recent Events

    • 06 Feb 2017 Status changed from not yet recruiting to recruiting.
    • 14 Sep 2016 Planned End Date changed from 1 Oct 2018 to 1 Aug 2019.
    • 14 Sep 2016 Planned primary completion date changed from 1 Aug 2018 to 1 Jun 2019.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top